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Background: Smoking is not associated with prostate cancer incidence in most studies, but associations between smoking and fatal prostate cancer have
been reported.
Methods: During 1992 and 2000, lifestyle information was assessed via questionnaires and personal interview in a cohort of 145 112 European men. Until
2009, 4623 incident cases of prostate cancer were identified, including 1517 cases of low-grade, 396 cases of high grade, 1516 cases of localised, 808 cases
of advanced disease, and 432 fatal cases. Multivariable Cox proportional hazards regression models were used to examine the association of smoking
status, smoking intensity, and smoking duration with the risk of incident and fatal prostate cancer.
Results: Compared with never smokers, current smokers had a reduced risk of prostate cancer (RR¼ 0.90, 95% CI: 0.83–0.97), which was statistically significant
for localised and low-grade disease, but not for advanced or high-grade disease. In contrast, heavy smokers (25þ cigarettes per day) andmen who had smoked
for a long time (40þ years) had a higher risk of prostate cancer death (RR¼ 1.81, 95% CI: 1.11–2.93; RR¼ 1.38, 95% CI: 1.01–1.87, respectively).
Conclusion: The observation of an increased prostate cancer mortality among heavy smokers confirms the results of previous prospective studies.
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Prostate cancer is the most common incident cancer in males in
developed countries (Ferlay et al, 2004). Owing to the large
international variation in prostate cancer incidence and mortality
rates, lifestyle is hypothesised to have a significant role in prostate
cancer development, though the precise aetiological factors have
not been identified. Cigarette smoking is still common in Europe,
with up to 40% of the adult male population smoking in 2008
(European Health for All statistical database: http://www.who.dk/).
Smoking is a well-known risk factor for several cancers, its
relationship with prostate cancer risk is less clear. In a recent meta-
analysis, current smoking was not associated with risk of prostate
cancer, but there was an increased risk among heavy smokers
(Huncharek et al, 2010). However, in that study, current smoking
was associated with increased prostate cancer mortality (Hunch-
arek et al, 2010) and a recent study showed that smoking at the
time of diagnosis was related to a higher risk of prostate cancer-
specific mortality (Gong et al, 2008).
To broaden our knowledge on the association of smoking with
prostate cancer incidence and mortality, we investigated prospec-
tively the association between cigarette smoking and prostate
cancer incidence and mortality in the European Prospective
Investigation into Cancer and Nutrition (EPIC).
MATERIALS AND METHODS
Study population. EPIC is a large prospective cohort study
conducted in 23 centers in 10 European countries (Denmark
(Aarhus, Copenhagen), France, Germany (Heidelberg, Potsdam),
UK (Cambridge, Oxford), Greece, Italy (Florence, Naples, Ragusa,
Turin, Varese), The Netherlands (Bilthoven, Utrecht), Norway,
Spain (Asturias, Granada, Murcia, Navarra, San Sebastian), Sweden
(Malmo¨, Umea)), including more than 500 000 participants. The
details of the recruitment process have been described previously
(Riboli et al, 2002). In brief, in most centers, the participants were
recruited from the general population. Italian and Spanish
participants were recruited among blood donors, members of
several health insurance programs, employees of several enter-
prises, civil servants, but also the general population. In Oxford,
half of the cohort consisted of ‘health conscious’ subjects from
across the UK. The cohorts of France, Naples, Norway, and
Utrecht included women only (Riboli et al, 2002). All subjects gave
written informed consent to use their questionnaire data and the
Internal Review Boards of the International Agency for Research
on Cancer and all EPIC recruitment centers approved the analyses
based on EPIC participants.
Of the 148 016 men without prevalent cancers (other than non-
melanoma skin cancer) eligible for analysis, men with incomplete
follow-up and missing information on smoking status were
excluded, leaving 145 112 men available for analysis.
Exposure assessment. At study recruitment, detailed information
was assessed on lifetime history of consumption of tobacco
products. This included questions on smoking status (current, past,
or never smoker), number of cigarettes currently smoked, average
number of cigarettes smoked over their lifetime, the age when
participants started and, if applicable, quit smoking.
Diet over the previous 12 months was assessed using dietary
assessment instruments that were specifically developed for each
participating country (Riboli et al, 2002). Baseline intake of energy
and nutrients was calculated from the dietary instruments applied
in each center (Riboli et al, 2002). Detailed information was also
assessed on leisure-time, occupational, and household physical
activity as well as education and marital status. Comparability of
non-dietary questions was ensured by a set of core questions that
were similar in all participating centers (Riboli et al, 2002). Height
and weight were measured in all EPIC centers except for Oxford,
where self-reported height and weight measurements were
available (Riboli et al, 2002).
Outcome assessment. Cancer diagnoses were based on population
registries in Denmark, Italy, the Netherlands, Spain, Sweden,
and UK. An active follow-up through study subjects and
next-of-kin information, the use of health insurance records, and
cancer and pathology registries were used in Germany and Greece.
Mortality data were obtained from either the cancer or mortality
registries at the regional or national level. Cancer cases were
identified by the end of the censoring periods ending between
December 2004 and December 2008, depending on the most recent
comparison of a center’s database with the respective cancer
registry. For Germany and Greece, the end of the follow-up was the
last known contact, date of diagnosis, or date of death, whichever
came first.
Definition of prostate cancer cases were based on the 10th
revision of the International Classification of Diseases (ICD-10)
and included all invasive malignant neoplasms, coded as C61.
Information on tumour TNM stage and histological grade was
collected from each center, where possible. Of 4623 incident
prostate cancer cases, information was available on stage for 50%
and on grade for 41%. Tumours were classified as localised (T0/T1/
T2 and N0/NX and M0, or stage coded in the recruitment center as
localised; n¼ 1516) or advanced (T3 or T4 and/or N1þ and/or
M1, or stage coded in the recruitment center as advanced or
metastatic; n¼ 808). Also, tumours were divided into low-
histological grade (Gleason score 2–7 or equivalent (cases coded
as well or moderately differentiated); n¼ 1517) or high grade
(Gleason score X8 or equivalent (cases coded as poorly
differentiated or undifferentiated); n¼ 396). During the follow-
up period, 432 fatal cases of prostate cancer were identified.
Statistical analysis. Cox proportional hazards regression was used
to examine the association of smoking status at recruitment,
smoking intensity (cigarettes per day in current smokers; mean
lifetime number of cigarettes per day in former smokers), duration
of smoking, and time since quit smoking. All analyses were
conducted separately for former and current smokers. Smoking
status was defined as never, former, current smokers; duration of
smoking aso10, 10–19, 20–29, 30–39, and 40þ years; time since
quit smoking aso5, 5–9, 10–19, and 20þ years ago; and number
of cigarettes smoked per day as 1–14, 15–24, and 25þ . Age was
the primary time metric in the Cox proportional hazards models.
Time at study entry was age at baseline, exit time was age when
participants were diagnosed with cancer, died, were lost to follow-
up, or were censored at the end of the follow-up period, whichever
came first. Exit time for the analysis of prostate cancer mortality
was age when participants died, were lost to follow-up, or were
censored at the end of the follow-up period, respectively. The
analyses were stratified by center and age at recruitment in 1-year
categories. Multivariate models were adjusted for body weight and
height at recruitment (as continuous variables), marital status
(single/divorced/widowed, married/living together, missing), edu-
cation (primary school or less, technical/professional school,
secondary school, university, missing), and vigorous physical
activity (none, p2 h per week, 42 h per week, missing). Models
that included additional adjustments for intake of energy, alcohol,
red meat, processed meat, tomato sauce, vitamin E, and calcium
did not materially alter the results and are not presented here. We
also simultaneously adjusted for smoking intesity and duration,
which, however, did not materially change the observed associa-
tions. Tests for trend were conducted using integer scores for
categories of smoking intensity, smoking duration, and years since
quit smoking. Sub-analyses were performed by stage and grade of
prostate cancer, by age at recruitment (o60, X60), and by BMI
(o25, X25 kgm 2). We tested for interaction of age and BMI
with smoking status in prostate cancer risk by including cross-
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product terms along with the main effect terms in the Cox
regression model. The statistical significance of the cross-product
terms was evaluated using the likelihood ratio test. We tested for
heterogeneity by outcome strata (that is, low-grade vs high-grade
tumours; localised vs advanced tumours) using the data augmenta-
tion method by Lunn and McNeil (1995). Heterogeneity
between countries was assessed using likelihood w2-tests.
All analyses were conducted using SAS version 9.1 (SAS Institute,
Cary, NC, USA).
RESULTS
Median follow-up time of the cohort was 11.9 (interquartile range
10.6–13.1) years. Former smokers were older and had a higher
BMI than never and current smokers (Table 1). Current smokers
had a higher intake of total energy, alcohol and red meat than
never and former smokers and were more often physically inactive.
Fomer smokers were more often married or lived together with a
partner. Never smokers more often had a university degree than
former and current smokers.
Current smokers had a significantly lower risk of prostate cancer
than never smokers (RR¼ 0.90, 95% CI: 0.83–0.97; Table 2). This
inverse association was evident for localised (RR¼ 0.86, 95% CI:
0.75–0.99) and low-grade disease (RR¼ 0.83, 95% CI: 0.72–0.95),
but not for advanced (RR¼ 1.05, 95% CI: 0.87–1.27) and high-
grade disease (RR¼ 1.13, 95% CI: 0.86–1.47).
Among former and current smokers, smoking intensity and
smoking duration were weakly inversely associated with prostate
cancer, with similar associations observed for localised and low-
grade disease (Table 2). No associations were observed for
advanced or high-grade disease. Former smokers who had smoked
for at least 40 years had an increased risk of advanced prostate
cancer compared with never smokers (RR¼ 1.45, 95% CI: 1.05–
2.00). Also, men who had recently, that is, o5 years before
recruitment, quit smoking had a non-significantly higher risk of
advanced disease than never smokers (RR¼ 1.32, 95% CI: 0.98–
1.76), but the tests for trend were not statistically significant. No
such associations were observed for high-grade disease (Table 2).
Simultaneously adjusting dose for duration did not materially alter
the observed associations (data not shown).
Current smoking was associated with a non-significant
increased risk of prostate cancer mortality compared with never
smokers (RR¼ 1.27, 95% CI: 0.98–1.65). In particular, a high
intensity of smoking (RR¼ 1.81, 95% CI: 1.11–2.93, 25þ
cigarettes per day vs non-smokers) and a long duration of smoking
(RR¼ 1.38, 95% CI: 1.01–1.87, 40þ years vs non-smokers) were
associated with a statistically significantly increased risk of prostate
cancer death (Table 2). In a joint-effects analysis, we combined
smoking status and smoking intensity (Figure 1) clearly showing
an association between heavy current smoking and prostate cancer
mortality, but no association for former smokers.
In a sub-analysis, we examined whether the categorization of
tumours with Gleason sum of 7 into the group of high-grade
cancer or as a separate group changed our results. For current
smokers, the RR was 0.79 (95% CI: 0.68–0.93) for tumours with
Gleason sum o7 and 1.03 (95% CI: 0.85–1.26) for tumours with
Gleason sum 7þ . Using three groups for Gleason sum, the results
were as follows: Gleason sum o7: RR¼ 0.79 (95% CI: 0.68–0.93);
Gleason sum¼ 7: RR¼ 0.94 (95% CI: 0.71–1.25); and Gleason sum
8þ RR¼ 1.13 (95% CI: 0.86–1.47).
We examined whether the associations between current
smoking and prostate cancer incidence and mortality differed by
country, but did not detect statistically significant heterogeneity (all
P-values 40.05). Also, results did not differ by BMI or age group
(P-values for interaction 40.05).
DISCUSSION
In this European cohort study, smoking was associated with a
small reduction in the risk of prostate cancer, which was significant
Table 1. Baseline characteristics of male EPIC participants by smoking status at baseline, 1992–2000
Never smokers Former smokers Current smokers
Median (Q1–Q3) Median (Q1–Q3) Median (Q1–Q3)
Age at recruitment (years) 51.4 (42.6–58.8) 54.8 (48.7–61.1) 51.9 (45.1–58.0)
BMI (kgm 2) 25.7 (23.6–28.1) 26.7 (24.6–29.0) 26.0 (23.8–28.5)
Body height (cm) 175.3 (170.1–180.0) 174.5 (170.0–179.0) 174.3 (169.5–179.2)
Marital status (%)a
Single 14.3 6.4 12.9
Married/living together 78.8 85.4 76.4
Divorced/separated 5.4 6.1 9.0
Widowed 1.4 2.1 1.6
Vigorous physical activity (%)a
None 31.4 35.1 41.8
p2h per week 21.1 20.9 17.2
42 h per week 20.9 22.4 18.2
Highest level of education (%)a
Primary school or less 25.8 31.5 36.6
Technical/professor school 22.8 25.6 26.3
Secondary school 17.0 14.9 15.9
University degree 32.4 25.4 20.1
Abbreviations: BMI¼body mass index; EPIC¼European Prospective Investigation into Cancer and Nutrition.
aSum does not add up to 100% because of missing information.
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for less aggressive disease; there was no association between
smoking and more aggressive incident disease. Smoking, in
particular heavy smoking, was associated with a significant increase
in risk of death from prostate cancer.
To date, most studies have not observed significant associations
of smoking with overall prostate cancer incidence (Hickey et al,
2001; Huncharek et al, 2010). In the current study, we found that
men who were smokers at recruitment had a 10% lower risk of
prostate cancer overall than never smokers, whereas no significant
association was seen for former smokers. However, the inverse
association of current smoking with prostate cancer risk was
confined to localised and low-grade disease. Similar inverse
associations between smoking and low-grade prostate cancer have
been reported in other studies (Giovannucci et al, 2007; Watters
et al, 2009). It is possible that this association may reflect a
detection bias, such that smokers are less likely to seek medical
attention and undergo medical tests and therefore are less likely to
be diagnosed with non-aggressive prostate cancer, or equally likely
non-smokers may be more inclined to seek medical attention and
be diagnosed with non-aggressive prostate cancer. We do not have
information on prostate cancer testing in this study population
and, thus, cannot evaluate the associations stratified by screening
behaviour. However, in the NIH-AARP cohort, the inverse
association between smoking and non-advanced prostate cancer
was observed among men who had undergone DRE and PSA
testing within the past 3 years and was, thus, independent of such
screening (Giovannucci et al, 2007; Watters et al, 2009). The
authors of that study speculated an inverse association between
smoking and prostate cancer incidence might partly be explained
by effects of smoking on circulating levels of insulin-like growth
factor-I and sex hormone binding globulin (Giovannucci et al,
2007; Watters et al, 2009). However, further research is needed to
clarify the true association between smoking and non-aggressive
prostate cancer.
Heavy smokers had an increased risk of dying from prostate
cancer, which is consistent with findings from previous US studies
(Hsing et al, 1990; Hsing et al, 1991; Coughlin et al, 1996;
Rodriguez et al, 1997; Giovannucci et al, 1999; Giovannucci et al,
2007; Rohrmann et al, 2007; Batty et al, 2008; Watters et al, 2009;
Weinmann et al, 2010). Zu and Giovannucci (2009) concluded
that, compared with never smokers, current smoking is associated
with an increased risk of about 30% for fatal prostate cancer;
depending on the comparison, the increase in risk ranges from
14% to 30% in the meta-analysis of Huncharek et al, (2010). These
estimates are similar to our estimate of a 27% higher risk of fatal
prostate cancer comparing current with never smokers. An
aggressive phenotype of prostate cancer may develop in smokers,
for example due to mutations in genes such as p53 (Giovannucci
et al, 1999). Continued exposure of the nascent prostate tumour to
carcinogens present in cigarette smoke and the loss of glutathione
S-transferase pi in prostate cancers (Lin et al, 2001), which
metabolises and inactivates a number of carcinogens, might
promote tumour progression (Roberts et al, 2003). Increased
oxidative stress may promote an accumulation of somatic
mutations in cancer cells and smoking-induced inflammation
could also contribute to tumour progression (Gong et al, 2008).
Two recent US studies have shown that men who smoked at
diagnosis were more likely to progress (Joshu et al, 2011) and to die
from the disease (Kenfield et al, 2011), but another study did not
find an association of smoking with biochemical recurrence of the
tumour (Moreira et al, 2010). However, all of these hypotheses
implicate an effect of smoking via disease progression. For this to
be true, one would also expect an association of heavy smoking
with advanced disease. However, our findings do not support the
hypothesis of an association between smoking and advanced or
high-grade disease.
In our analysis, we were able to take into account several
potential confounders of the association between cigarette smoking
and prostate cancer risk, that is, body height and weight, education,
marital status, and vigorous physical activity. The follow-up period
in EPIC is relatively short (median of 11.9 years) compared with
other cohort studies. However, this is not necessarily a disadvan-
tage because some studies have shown that there seems to be a
relationship between recent smoking and prostate cancer risk. A
0
0.5
1
1.5
2
2.5
3
3.5
Ne
ve
r s
mo
ke
r
Fo
rm
er 
< 1
5 c
iga
ret
tes
 pe
r d
ay
Fo
rm
er 
15
–
24
 cig
are
tte
s p
er 
da
y
Fo
rm
er 
25
+ c
iga
ret
tes
 pe
r d
ay
Cu
rre
nt 
< 1
5 c
iga
ret
tes
 pe
r d
ay
Cu
rre
nt 
15
–
24
 cig
are
tte
s p
er 
da
y
Cu
rre
nt 
25
+ c
iga
ret
tes
 pe
r d
ay
Ne
ve
r s
mo
ke
r
Fo
rm
er 
< 1
5 c
iga
ret
tes
 pe
r d
ay
Fo
rm
er 
15
–
24
 cig
are
tte
s p
er 
da
y
Fo
rm
er 
25
+ c
iga
ret
tes
 pe
r d
ay
Cu
rre
nt 
< 1
5 c
iga
ret
tes
 pe
r d
ay
Cu
rre
nt 
15
–
24
 cig
are
tte
s p
er 
da
y
Cu
rre
nt 
25
+ c
iga
ret
tes
 pe
r d
ay
H
az
ar
d 
ra
tio
(A) Prostate cancer incidence (B) Prostate cancer mortality
Figure 1. Association of smoking intensity (cigarettes per day by smoking status) and (A) prostate cancer incidence and (B) prostate cancer mortality
in EPIC.
BRITISH JOURNAL OF CANCER Smoking and the risk of prostate cancer
712 www.bjcancer.com |DOI:10.1038/bjc.2012.520
study by Hsing et al (1991) with 26 years of follow-up observed an
attenuation of the association between smoking and prostate
cancer mortality with increasing follow-up time. Similarly, an
association between cigarette smoking and prostate cancer
mortality was seen in the first 10 years of follow-up in a US
cohort study but not when considering total follow-up time
(Rohrmann et al, 2007). However, median follow-up time in our
study among men who died of prostate cancer was only 5.0 years
and when stratifying by follow-up time, we observed almost the
same associations between smoking status at baseline and risk of
dying from prostate cancer for follow-up periods of 0–o5 years
(HR¼ 1.15, 95% CI: 0.89–1.50 smokers vs non-smokers) and 5þ
years (HR¼ 1.21, 95% CI: 0.90–1.61). When relying on a man’s
smoking status as reported at baseline, it is likely that there is less
misclassification of smoking status earlier in follow-up than later in
follow-up, when men may have subsequently quit smoking. A
further limitation is possible misclassification of cause of death,
that is, men with prostate cancer did not actually die of prostate
cancer but of co-morbidity, however, the cause of death was
attributed to prostate cancer. We relied on the underlying cause of
death on death certificates and did not verify cause of death from
medical records. However, in the Health Professionals Follow-up
Study, re-examination of medical records by blinded reviewers had
shown that deaths attributed to prostate cancer were likely to be
truly prostate cancer specific (Giovannucci et al, 1999). Also, we do
not have systematic information on prostate cancer sreening
behaviour across the cohorts. We cannot exclude that screening
behaviour differs between countries and is associated with the
prevalence of smoking. The prevalence of smoking varies between
the participating centers and countries, with rates below 25% in
Sweden and Germany (as well as the British health-conscious
cohort) and 440% in Spain and Greece. Never-smoking rates
ranged between 26% in Greece and 44% in Sweden. Thus, we
cannot exclude that our results are affected by some residual
confounding arising from differences in smoking prevalence and
screening behaviour. Finally, we have conducted several sub-
analyses and, thus, cannot exclude the some of our findings might
be due to chance.
In conclusion, smoking appears to be associated with a lower
risk of less aggressive prostate cancer, while heavy smoking is
associated with an increased risk of prostate cancer death. Future
studies are warranted to examine whether these associations are
due to different health-care seeking behaviour between smokers
and non-smokers, and whether stopping smoking at the time of
prostate cancer diagnosis will decrease the risk of dying from this
disease as well as many other diseases.
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